Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Plasticity of the Mycobacterium tuberculosis respiratory chain and its impact on tuberculosis drug development.

Beites T, O'Brien K, Tiwari D, Engelhart CA, Walters S, Andrews J, Yang HJ, Sutphen ML, Weiner DM, Dayao EK, Zimmerman M, Prideaux B, Desai PV, Masquelin T, Via LE, Dartois V, Boshoff HI, Barry CE 3rd, Ehrt S, Schnappinger D.

Nat Commun. 2019 Oct 31;10(1):4970. doi: 10.1038/s41467-019-12956-2.

2.

Inhibition of CorA-Dependent Magnesium Homeostasis Is Cidal in Mycobacterium tuberculosis.

Park Y, Ahn YM, Jonnala S, Oh S, Fisher JM, Goodwin MB, Ioerger TR, Via LE, Bayliss T, Green SR, Ray PC, Wyatt PG, Barry CE 3rd, Boshoff HI.

Antimicrob Agents Chemother. 2019 Sep 23;63(10). pii: e01006-19. doi: 10.1128/AAC.01006-19. Print 2019 Oct.

PMID:
31383669
3.

Author Correction: The wide utility of rabbits as models of human diseases.

Esteves PJ, Abrantes J, Baldauf HM, BenMohamed L, Chen Y, Christensen N, González-Gallego J, Giacani L, Hu J, Kaplan G, Keppler OT, Knight KL, Kong XP, Lanning DK, Le Pendu J, de Matos AL, Liu J, Liu S, Lopes AM, Lu S, Lukehart S, Manabe YC, Neves F, McFadden G, Pan R, Peng X, de Sousa-Pereira P, Pinheiro A, Rahman M, Ruvoën-Clouet N, Subbian S, Tuñón MJ, van der Loo W, Vaine M, Via LE, Wang S, Mage R.

Exp Mol Med. 2019 Jul 4;51(7):71. doi: 10.1038/s12276-019-0252-0.

4.

Changes in inflammatory protein and lipid mediator profiles persist after antitubercular treatment of pulmonary and extrapulmonary tuberculosis: A prospective cohort study.

Vinhaes CL, Oliveira-de-Souza D, Silveira-Mattos PS, Nogueira B, Shi R, Wei W, Yuan X, Zhang G, Cai Y, Barry CE 3rd, Via LE, Fukutani KF, Andrade BB, Mayer-Barber KD.

Cytokine. 2019 Nov;123:154759. doi: 10.1016/j.cyto.2019.154759. Epub 2019 Jun 18.

PMID:
31226436
5.

Molecular degree of perturbation of plasma inflammatory markers associated with tuberculosis reveals distinct disease profiles between Indian and Chinese populations.

Oliveira-de-Souza D, Vinhaes CL, Arriaga MB, Kumar NP, Cubillos-Angulo JM, Shi R, Wei W, Yuan X, Zhang G, Cai Y, Barry CE 3rd, Via LE, Sher A, Babu S, Mayer-Barber KD, Nakaya HI, Fukutani KF, Andrade BB.

Sci Rep. 2019 May 29;9(1):8002. doi: 10.1038/s41598-019-44513-8.

6.

Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization.

Strydom N, Gupta SV, Fox WS, Via LE, Bang H, Lee M, Eum S, Shim T, Barry CE 3rd, Zimmerman M, Dartois V, Savic RM.

PLoS Med. 2019 Apr 2;16(4):e1002773. doi: 10.1371/journal.pmed.1002773. eCollection 2019 Apr.

7.

Discovery and Structure-Activity-Relationship Study of N-Alkyl-5-hydroxypyrimidinone Carboxamides as Novel Antitubercular Agents Targeting Decaprenylphosphoryl-β-d-ribose 2'-Oxidase.

Oh S, Park Y, Engelhart CA, Wallach JB, Schnappinger D, Arora K, Manikkam M, Gac B, Wang H, Murgolo N, Olsen DB, Goodwin M, Sutphin M, Weiner DM, Via LE, Boshoff HIM, Barry CE 3rd.

J Med Chem. 2018 Nov 21;61(22):9952-9965. doi: 10.1021/acs.jmedchem.8b00883. Epub 2018 Nov 5.

8.

Storage lipid studies in tuberculosis reveal that foam cell biogenesis is disease-specific.

Guerrini V, Prideaux B, Blanc L, Bruiners N, Arrigucci R, Singh S, Ho-Liang HP, Salamon H, Chen PY, Lakehal K, Subbian S, O'Brien P, Via LE, Barry CE 3rd, Dartois V, Gennaro ML.

PLoS Pathog. 2018 Aug 30;14(8):e1007223. doi: 10.1371/journal.ppat.1007223. eCollection 2018 Aug.

9.

A semi-automatic technique to quantify complex tuberculous lung lesions on 18F-fluorodeoxyglucose positron emission tomography/computerised tomography images.

Malherbe ST, Dupont P, Kant I, Ahlers P, Kriel M, Loxton AG, Chen RY, Via LE, Thienemann F, Wilkinson RJ, Barry CE 3rd, Griffith-Richards S, Ellman A, Ronacher K, Winter J, Walzl G, Warwick JM; Catalysis Biomarker Consortium.

EJNMMI Res. 2018 Jun 25;8(1):55. doi: 10.1186/s13550-018-0411-7.

10.

Computed Tomography-Based Biomarker for Longitudinal Assessment of Disease Burden in Pulmonary Tuberculosis.

Gordaliza PM, Muñoz-Barrutia A, Via LE, Sharpe S, Desco M, Vaquero JJ.

Mol Imaging Biol. 2019 Feb;21(1):19-24. doi: 10.1007/s11307-018-1215-x.

PMID:
29845428
11.

The wide utility of rabbits as models of human diseases.

Esteves PJ, Abrantes J, Baldauf HM, BenMohamed L, Chen Y, Christensen N, González-Gallego J, Giacani L, Hu J, Kaplan G, Keppler OT, Knight KL, Kong XP, Lanning DK, Le Pendu J, de Matos AL, Liu J, Liu S, Lopes AM, Lu S, Lukehart S, Manabe YC, Neves F, McFadden G, Pan R, Peng X, de Sousa-Pereira P, Pinheiro A, Rahman M, Ruvoën-Clouet N, Subbian S, Tuñón MJ, van der Loo W, Vaine M, Via LE, Wang S, Mage R.

Exp Mol Med. 2018 May 22;50(5):66. doi: 10.1038/s12276-018-0094-1. Review. Erratum in: Exp Mol Med. 2019 Jul 4;51(7):71.

12.

Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial.

Chen RY, Via LE, Dodd LE, Walzl G, Malherbe ST, Loxton AG, Dawson R, Wilkinson RJ, Thienemann F, Tameris M, Hatherill M, Diacon AH, Liu X, Xing J, Jin X, Ma Z, Pan S, Zhang G, Gao Q, Jiang Q, Zhu H, Liang L, Duan H, Song T, Alland D, Tartakovsky M, Rosenthal A, Whalen C, Duvenhage M, Cai Y, Goldfeder LC, Arora K, Smith B, Winter J, Barry Iii CE; Predict TB Study Group.

Gates Open Res. 2017 Nov 6;1:9. doi: 10.12688/gatesopenres.12750.1.

13.

Corrigendum: Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure.

Malherbe ST, Shenai S, Ronacher K, Loxton AG, Dolganov G, Kriel M, Van T, Chen RY, Warwick J, Via LE, Song T, Lee M, Schoolnik G, Tromp G, Alland D, Barry CE 3rd, Winter J, Walzl G; Catalysis TB–Biomarker Consortium.

Nat Med. 2017 Dec 7;23(12):1499. doi: 10.1038/nm1217-1499a.

14.

Extreme Drug Tolerance of Mycobacterium tuberculosis in Caseum.

Sarathy JP, Via LE, Weiner D, Blanc L, Boshoff H, Eugenin EA, Barry CE 3rd, Dartois VA.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e02266-17. doi: 10.1128/AAC.02266-17. Print 2018 Feb.

15.

Host blood RNA signatures predict the outcome of tuberculosis treatment.

Thompson EG, Du Y, Malherbe ST, Shankar S, Braun J, Valvo J, Ronacher K, Tromp G, Tabb DL, Alland D, Shenai S, Via LE, Warwick J, Aderem A, Scriba TJ, Winter J, Walzl G, Zak DE; Catalysis TB–Biomarker Consortium.

Tuberculosis (Edinb). 2017 Dec;107:48-58. doi: 10.1016/j.tube.2017.08.004. Epub 2017 Aug 12.

16.

Interferon-gamma response to the treatment of active pulmonary and extra-pulmonary tuberculosis.

Liang L, Shi R, Liu X, Yuan X, Zheng S, Zhang G, Wang W, Wang J, England K, Via LE, Cai Y, Goldfeder LC, Dodd LE, Barry CE, Chen RY.

Int J Tuberc Lung Dis. 2017 Oct 1;21(10):1145-1149. doi: 10.5588/ijtld.16.0880.

17.

Evaluation of a Rapid Molecular Drug-Susceptibility Test for Tuberculosis.

Xie YL, Chakravorty S, Armstrong DT, Hall SL, Via LE, Song T, Yuan X, Mo X, Zhu H, Xu P, Gao Q, Lee M, Lee J, Smith LE, Chen RY, Joh JS, Cho Y, Liu X, Ruan X, Liang L, Dharan N, Cho SN, Barry CE 3rd, Ellner JJ, Dorman SE, Alland D.

N Engl J Med. 2017 Sep 14;377(11):1043-1054. doi: 10.1056/NEJMoa1614915.

18.

An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions.

Sarathy JP, Liang HH, Weiner D, Gonzales J, Via LE, Dartois V.

J Vis Exp. 2017 May 8;(123). doi: 10.3791/55559.

19.

The within-host population dynamics of Mycobacterium tuberculosis vary with treatment efficacy.

Trauner A, Liu Q, Via LE, Liu X, Ruan X, Liang L, Shi H, Chen Y, Wang Z, Liang R, Zhang W, Wei W, Gao J, Sun G, Brites D, England K, Zhang G, Gagneux S, Barry CE 3rd, Gao Q.

Genome Biol. 2017 Apr 19;18(1):71. doi: 10.1186/s13059-017-1196-0.

20.

Corrigendum: Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure.

Malherbe ST, Shenai S, Ronacher K, Loxton AG, Dolganov G, Kriel M, Van T, Chen RY, Warwick J, Via LE, Song T, Lee M, Schoolnik G, Tromp G, Alland D, Barry CE 3rd, Winter J, Walzl G; Catalysis TB–Biomarker Consortium.

Nat Med. 2017 Apr 7;23(4):526. doi: 10.1038/nm0417-526a. No abstract available.

PMID:
28388609
21.

Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance.

Manson AL, Cohen KA, Abeel T, Desjardins CA, Armstrong DT, Barry CE 3rd, Brand J; TBResist Global Genome Consortium, Chapman SB, Cho SN, Gabrielian A, Gomez J, Jodals AM, Joloba M, Jureen P, Lee JS, Malinga L, Maiga M, Nordenberg D, Noroc E, Romancenco E, Salazar A, Ssengooba W, Velayati AA, Winglee K, Zalutskaya A, Via LE, Cassell GH, Dorman SE, Ellner J, Farnia P, Galagan JE, Rosenthal A, Crudu V, Homorodean D, Hsueh PR, Narayanan S, Pym AS, Skrahina A, Swaminathan S, Van der Walt M, Alland D, Bishai WR, Cohen T, Hoffner S, Birren BW, Earl AM.

Nat Genet. 2017 Mar;49(3):395-402. doi: 10.1038/ng.3767. Epub 2017 Jan 16.

22.

Detection of Isoniazid-, Fluoroquinolone-, Amikacin-, and Kanamycin-Resistant Tuberculosis in an Automated, Multiplexed 10-Color Assay Suitable for Point-of-Care Use.

Chakravorty S, Roh SS, Glass J, Smith LE, Simmons AM, Lund K, Lokhov S, Liu X, Xu P, Zhang G, Via LE, Shen Q, Ruan X, Yuan X, Zhu HZ, Viazovkina E, Shenai S, Rowneki M, Lee JS, Barry CE 3rd, Gao Q, Persing D, Kwiatkawoski R, Jones M, Gall A, Alland D.

J Clin Microbiol. 2016 Dec 28;55(1):183-198. doi: 10.1128/JCM.01771-16. Print 2017 Jan.

23.

Very Low Doses of Mycobacterium tuberculosis Yield Diverse Host Outcomes in Common Marmosets (Callithrix jacchus).

Cadena AM, Klein EC, White AG, Tomko JA, Chedrick CL, Reed DS, Via LE, Lin PL, Flynn JL.

Comp Med. 2016;66(5):412-419.

24.

Essential but Not Vulnerable: Indazole Sulfonamides Targeting Inosine Monophosphate Dehydrogenase as Potential Leads against Mycobacterium tuberculosis.

Park Y, Pacitto A, Bayliss T, Cleghorn LA, Wang Z, Hartman T, Arora K, Ioerger TR, Sacchettini J, Rizzi M, Donini S, Blundell TL, Ascher DB, Rhee K, Breda A, Zhou N, Dartois V, Jonnala SR, Via LE, Mizrahi V, Epemolu O, Stojanovski L, Simeons F, Osuna-Cabello M, Ellis L, MacKenzie CJ, Smith AR, Davis SH, Murugesan D, Buchanan KI, Turner PA, Huggett M, Zuccotto F, Rebollo-Lopez MJ, Lafuente-Monasterio MJ, Sanz O, Diaz GS, Lelièvre J, Ballell L, Selenski C, Axtman M, Ghidelli-Disse S, Pflaumer H, Bösche M, Drewes G, Freiberg GM, Kurnick MD, Srikumaran M, Kempf DJ, Green SR, Ray PC, Read K, Wyatt P, Barry CE 3rd, Boshoff HI.

ACS Infect Dis. 2017 Jan 13;3(1):18-33. doi: 10.1021/acsinfecdis.6b00103. Epub 2016 Oct 17.

25.

Prediction of Drug Penetration in Tuberculosis Lesions.

Sarathy JP, Zuccotto F, Hsinpin H, Sandberg L, Via LE, Marriner GA, Masquelin T, Wyatt P, Ray P, Dartois V.

ACS Infect Dis. 2016 Aug 12;2(8):552-63. doi: 10.1021/acsinfecdis.6b00051. Epub 2016 Jul 6.

26.

Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure.

Malherbe ST, Shenai S, Ronacher K, Loxton AG, Dolganov G, Kriel M, Van T, Chen RY, Warwick J, Via LE, Song T, Lee M, Schoolnik G, Tromp G, Alland D, Barry CE 3rd, Winter J, Walzl G; Catalysis TB–Biomarker Consortium, Lucas L, Spuy GV, Stanley K, Thiart L, Smith B, Du Plessis N, Beltran CG, Maasdorp E, Ellmann A, Choi H, Joh J, Dodd LE, Allwood B, Koegelenberg C, Vorster M, Griffith-Richards S.

Nat Med. 2016 Oct;22(10):1094-1100. doi: 10.1038/nm.4177. Epub 2016 Sep 5. Erratum in: Nat Med. 2017 Apr 7;23 (4):526. Nat Med. 2017 Dec 7;23 (12 ):1499.

27.

Correction to Absolute Quantitative MALDI Imaging Mass Spectrometry: A Case of Rifampicin in Liver Tissues.

Chumbley CW, Reyzer ML, Allen JL, Marriner GA, Via LE, Barry CE 3rd, Caprioli RM.

Anal Chem. 2016 Sep 6;88(17):8920. doi: 10.1021/acs.analchem.6b03125. Epub 2016 Aug 19. No abstract available.

28.

Bacterial Loads Measured by the Xpert MTB/RIF Assay as Markers of Culture Conversion and Bacteriological Cure in Pulmonary TB.

Shenai S, Ronacher K, Malherbe S, Stanley K, Kriel M, Winter J, Peppard T, Barry CE, Wang J, Dodd LE, Via LE, Barry CE 3rd, Walzl G, Alland D.

PLoS One. 2016 Aug 10;11(8):e0160062. doi: 10.1371/journal.pone.0160062. eCollection 2016.

29.

High Persister Mutants in Mycobacterium tuberculosis.

Torrey HL, Keren I, Via LE, Lee JS, Lewis K.

PLoS One. 2016 May 13;11(5):e0155127. doi: 10.1371/journal.pone.0155127. eCollection 2016.

30.

Inflammatory signaling in human tuberculosis granulomas is spatially organized.

Marakalala MJ, Raju RM, Sharma K, Zhang YJ, Eugenin EA, Prideaux B, Daudelin IB, Chen PY, Booty MG, Kim JH, Eum SY, Via LE, Behar SM, Barry CE 3rd, Mann M, Dartois V, Rubin EJ.

Nat Med. 2016 May;22(5):531-8. doi: 10.1038/nm.4073. Epub 2016 Apr 4.

31.

Linezolid Trough Concentrations Correlate with Mitochondrial Toxicity-Related Adverse Events in the Treatment of Chronic Extensively Drug-Resistant Tuberculosis.

Song T, Lee M, Jeon HS, Park Y, Dodd LE, Dartois V, Follman D, Wang J, Cai Y, Goldfeder LC, Olivier KN, Xie Y, Via LE, Cho SN, Barry CE 3rd, Chen RY.

EBioMedicine. 2015 Oct 9;2(11):1627-33. doi: 10.1016/j.ebiom.2015.09.051. eCollection 2015 Nov.

32.

Absolute Quantitative MALDI Imaging Mass Spectrometry: A Case of Rifampicin in Liver Tissues.

Chumbley CW, Reyzer ML, Allen JL, Marriner GA, Via LE, Barry CE 3rd, Caprioli RM.

Anal Chem. 2016 Feb 16;88(4):2392-8. doi: 10.1021/acs.analchem.5b04409. Epub 2016 Feb 5. Erratum in: Anal Chem. 2016 Sep 6;88(17):8920.

33.

Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study.

Yuen CM, Kurbatova EV, Tupasi T, Caoili JC, Van Der Walt M, Kvasnovsky C, Yagui M, Bayona J, Contreras C, Leimane V, Ershova J, Via LE, Kim H, Akksilp S, Kazennyy BY, Volchenkov GV, Jou R, Kliiman K, Demikhova OV, Vasilyeva IA, Dalton T, Cegielski JP.

PLoS Med. 2015 Dec 29;12(12):e1001932. doi: 10.1371/journal.pmed.1001932. eCollection 2015 Dec.

34.

Within patient microevolution of Mycobacterium tuberculosis correlates with heterogeneous responses to treatment.

Liu Q, Via LE, Luo T, Liang L, Liu X, Wu S, Shen Q, Wei W, Ruan X, Yuan X, Zhang G, Barry CE 3rd, Gao Q.

Sci Rep. 2015 Dec 1;5:17507. doi: 10.1038/srep17507.

35.

Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug Resistance.

Cegielski JP, Kurbatova E, van der Walt M, Brand J, Ershova J, Tupasi T, Caoili JC, Dalton T, Contreras C, Yagui M, Bayona J, Kvasnovsky C, Leimane V, Kuksa L, Chen MP, Via LE, Hwang SH, Wolfgang M, Volchenkov GV, Somova T, Smith SE, Akksilp S, Wattanaamornkiet W, Kim HJ, Kim CK, Kazennyy BY, Khorosheva T, Kliiman K, Viiklepp P, Jou R, Huang AS, Vasilyeva IA, Demikhova OV; Global PETTS Investigators, Lancaster J, Odendaal R, Diem L, Perez TC, Gler T, Tan K, Bonilla C, Jave O, Asencios L, Yale G, Suarez C, Walker AT, Norvaisha I, Skenders G, Sture I, Riekstina V, Cirule A, Sigman E, Cho SN, Cai Y, Eum S, Lee J, Park S, Jeon D, Shamputa IC, Metchock B, Kuznetsova T, Akksilp R, Sitti W, Inyapong J, Kiryanova EV, Degtyareva I, Nemtsova ES, Levina K, Danilovits M, Kummik T, Lei YC, Huang WL, Erokhin VV, Chernousova LN, Andreevskaya SN, Larionova EE, Smirnova TG.

Clin Infect Dis. 2016 Feb 15;62(4):418-430. doi: 10.1093/cid/civ910. Epub 2015 Oct 27.

36.

The association between sterilizing activity and drug distribution into tuberculosis lesions.

Prideaux B, Via LE, Zimmerman MD, Eum S, Sarathy J, O'Brien P, Chen C, Kaya F, Weiner DM, Chen PY, Song T, Lee M, Shim TS, Cho JS, Kim W, Cho SN, Olivier KN, Barry CE 3rd, Dartois V.

Nat Med. 2015 Oct;21(10):1223-7. doi: 10.1038/nm.3937. Epub 2015 Sep 7.

37.

Intratracheal exposure of common marmosets to MERS-CoV Jordan-n3/2012 or MERS-CoV EMC/2012 isolates does not result in lethal disease.

Johnson RF, Via LE, Kumar MR, Cornish JP, Yellayi S, Huzella L, Postnikova E, Oberlander N, Bartos C, Ork BL, Mazur S, Allan C, Holbrook MR, Solomon J, Johnson JC, Pickel J, Hensley LE, Jahrling PB.

Virology. 2015 Nov;485:422-30. doi: 10.1016/j.virol.2015.07.013. Epub 2015 Sep 3.

38.

Mathematical Model of Oxygen Transport in Tuberculosis Granulomas.

Datta M, Via LE, Chen W, Baish JW, Xu L, Barry CE 3rd, Jain RK.

Ann Biomed Eng. 2016 Apr;44(4):863-72. doi: 10.1007/s10439-015-1415-3. Epub 2015 Aug 8.

39.

Host-Mediated Bioactivation of Pyrazinamide: Implications for Efficacy, Resistance, and Therapeutic Alternatives.

Via LE, Savic R, Weiner DM, Zimmerman MD, Prideaux B, Irwin SM, Lyon E, O'Brien P, Gopal P, Eum S, Lee M, Lanoix JP, Dutta NK, Shim T, Cho JS, Kim W, Karakousis PC, Lenaerts A, Nuermberger E, Barry CE 3rd, Dartois V.

ACS Infect Dis. 2015 May 8;1(5):203-214.

40.

Additional drug resistance of multidrug-resistant tuberculosis in patients in 9 countries.

Kurbatova EV, Dalton T, Ershova J, Tupasi T, Caoili JC, Van Der Walt M, Kvasnovsky C, Yagui M, Bayona J, Contreras C, Leimane V, Via LE, Kim H, Akksilp S, Kazennyy BY, Volchenkov GV, Jou R, Kliiman K, Demikhova OV, Cegielski JP.

Emerg Infect Dis. 2015 Jun;21(6):977-83. doi: 10.3201/eid2106.141329.

41.

A sterilizing tuberculosis treatment regimen is associated with faster clearance of bacteria in cavitary lesions in marmosets.

Via LE, England K, Weiner DM, Schimel D, Zimmerman MD, Dayao E, Chen RY, Dodd LE, Richardson M, Robbins KK, Cai Y, Hammoud D, Herscovitch P, Dartois V, Flynn JL, Barry CE 3rd.

Antimicrob Agents Chemother. 2015 Jul;59(7):4181-9. doi: 10.1128/AAC.00115-15. Epub 2015 May 4.

42.

Comparative Evaluation of Sloppy Molecular Beacon and Dual-Labeled Probe Melting Temperature Assays to Identify Mutations in Mycobacterium tuberculosis Resulting in Rifampin, Fluoroquinolone and Aminoglycoside Resistance.

Roh SS, Smith LE, Lee JS, Via LE, Barry CE 3rd, Alland D, Chakravorty S.

PLoS One. 2015 May 4;10(5):e0126257. doi: 10.1371/journal.pone.0126257. eCollection 2015.

43.

Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies.

Kurbatova EV, Cegielski JP, Lienhardt C, Akksilp R, Bayona J, Becerra MC, Caoili J, Contreras C, Dalton T, Danilovits M, Demikhova OV, Ershova J, Gammino VM, Gelmanova I, Heilig CM, Jou R, Kazennyy B, Keshavjee S, Kim HJ, Kliiman K, Kvasnovsky C, Leimane V, Mitnick CD, Quelapio I, Riekstina V, Smith SE, Tupasi T, van der Walt M, Vasilyeva IA, Via LE, Viiklepp P, Volchenkov G, Walker AT, Wolfgang M, Yagui M, Zignol M.

Lancet Respir Med. 2015 Mar;3(3):201-9. doi: 10.1016/S2213-2600(15)00036-3. Epub 2015 Feb 26.

44.

Granzyme B-expressing neutrophils correlate with bacterial load in granulomas from Mycobacterium tuberculosis-infected cynomolgus macaques.

Mattila JT, Maiello P, Sun T, Via LE, Flynn JL.

Cell Microbiol. 2015 Aug;17(8):1085-97. doi: 10.1111/cmi.12428. Epub 2015 Mar 12.

45.

Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery.

Datta M, Via LE, Kamoun WS, Liu C, Chen W, Seano G, Weiner DM, Schimel D, England K, Martin JD, Gao X, Xu L, Barry CE 3rd, Jain RK.

Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1827-32. doi: 10.1073/pnas.1424563112. Epub 2015 Jan 26.

46.

PET/CT imaging reveals a therapeutic response to oxazolidinones in macaques and humans with tuberculosis.

Coleman MT, Chen RY, Lee M, Lin PL, Dodd LE, Maiello P, Via LE, Kim Y, Marriner G, Dartois V, Scanga C, Janssen C, Wang J, Klein E, Cho SN, Barry CE 3rd, Flynn JL.

Sci Transl Med. 2014 Dec 3;6(265):265ra167. doi: 10.1126/scitranslmed.3009500.

47.

PET/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosis.

Chen RY, Dodd LE, Lee M, Paripati P, Hammoud DA, Mountz JM, Jeon D, Zia N, Zahiri H, Coleman MT, Carroll MW, Lee JD, Jeong YJ, Herscovitch P, Lahouar S, Tartakovsky M, Rosenthal A, Somaiyya S, Lee S, Goldfeder LC, Cai Y, Via LE, Park SK, Cho SN, Barry CE 3rd.

Sci Transl Med. 2014 Dec 3;6(265):265ra166. doi: 10.1126/scitranslmed.3009501.

48.

Genotypic susceptibility testing of Mycobacterium tuberculosis isolates for amikacin and kanamycin resistance by use of a rapid sloppy molecular beacon-based assay identifies more cases of low-level drug resistance than phenotypic Lowenstein-Jensen testing.

Chakravorty S, Lee JS, Cho EJ, Roh SS, Smith LE, Lee J, Kim CT, Via LE, Cho SN, Barry CE 3rd, Alland D.

J Clin Microbiol. 2015 Jan;53(1):43-51. doi: 10.1128/JCM.02059-14. Epub 2014 Oct 22.

49.

Nuclear imaging: a powerful novel approach for tuberculosis.

Johnson DH, Via LE, Kim P, Laddy D, Lau CY, Weinstein EA, Jain S.

Nucl Med Biol. 2014 Nov-Dec;41(10):777-84. doi: 10.1016/j.nucmedbio.2014.08.005. Epub 2014 Aug 7. Review.

50.

Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis.

Cegielski JP, Dalton T, Yagui M, Wattanaamornkiet W, Volchenkov GV, Via LE, Van Der Walt M, Tupasi T, Smith SE, Odendaal R, Leimane V, Kvasnovsky C, Kuznetsova T, Kurbatova E, Kummik T, Kuksa L, Kliiman K, Kiryanova EV, Kim H, Kim CK, Kazennyy BY, Jou R, Huang WL, Ershova J, Erokhin VV, Diem L, Contreras C, Cho SN, Chernousova LN, Chen MP, Caoili JC, Bayona J, Akksilp S; Global Preserving Effective TB Treatment Study (PETTS) Investigators.

Clin Infect Dis. 2014 Oct 15;59(8):1049-63. doi: 10.1093/cid/ciu572. Epub 2014 Jul 23.

Supplemental Content

Support Center